 | |
| Clinical data | |
|---|---|
| Trade names | Ypozane |
| Other names | TZP-4238; Gestoxarone acetate; 2-Oxachloromadinone acetate; 17α-Acetoxy-6-chloro-2-oxa-6-dehydroprogesterone; 17α-Acetoxy-6-chloro-2-oxapregna-4,6-diene-3,20-dione |
| Routes of administration | By mouth (tablets) |
| Drug class | Steroidal antiandrogen;Progestogen;Progestin;Progestogen ester |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | Osaterone acetate: 90% 15β-Hydroxyosaterone acetate: 80%[3] (Both mainly toalbumin)[3] |
| Metabolism | Liver[3] |
| Metabolites | 15β-Hydroxyosaterone acetate[3] |
| Eliminationhalf-life | Dogs: 80 hours to 197 ± 109 hours[3][4] |
| Excretion | Bile: 60%[3] Urine: 25%[3] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.215.750 |
| Chemical and physical data | |
| Formula | C22H27ClO5 |
| Molar mass | 406.90 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Osaterone acetate, sold under the brand nameYpozane, is amedication which is used inveterinary medicine for the treatment ofenlarged prostate in dogs.[3][5][6] It is givenby mouth.[3]
Osaterone acetate is anantiandrogen, and hence is anantagonist of theandrogen receptor, thebiological target ofandrogens liketestosterone anddihydrotestosterone.[3] It is also a progestin, or asyntheticprogestogen, and hence is anagonist of theprogesterone receptor, the biological target of progestogens likeprogesterone.[3]
Osaterone acetate was introduced for veterinary use in 2007.[1][3][7][8]
Osaterone acetate is used inveterinary medicine for the treatment ofbenign prostatic hyperplasia (BPH) in dogs.[3][5][6] It has been found to produce remission of clinical symptoms of BPH in 83% of dogs for six months after a single one-week course of treatment,[9] and can be used long-term.[6]
Osaterone acetate comes in the form of 1.875 mg, 3.75 mg, 7.5 mg, and 15 mgoraltablets for veterinary use.[3]
Side effects of osaterone acetate include diminishedsperm quality (for up to 6 weeks post-treatment), transient elevation ofliver enzymes (caution should be observed with knownliver disease),vomiting,diarrhea,polyuria/polydipsia,lethargy, andhyperplasia of themammary glands.[10] It can also decreasecortisol levels, interfere withadrenocorticotropic hormone response, induce or exacerbateadrenal insufficiency, and exacerbatediabetes mellitus.[11][10]
Osaterone acetate is asteroidal antiandrogen,progestin, andantigonadotropin.[3] It has virtually noestrogenic orandrogenic activity.[5] Itsside-effect profile indicates that it possesses clinically relevantglucocorticoid activity.[11][10] An active metabolite of osaterone acetate, 15β-hydroxyosaterone acetate, has potent antiandrogenic activity similarly to osaterone acetate.[3] Osaterone acetate treats BPH in dogs by reducing the actions ofandrogens in theprostate gland.[3]
The majoractive metabolite of osaterone acetate is 15β-hydroxyosaterone acetate.[3] Osaterone acetate has a longbiological half-life of 80 hours to 197 ± 109 hours in dogs.[3][4]
Osaterone acetate, also known as 2-oxachloromadinone acetate, as well as 17α-acetoxy-6-chloro-2-oxa-6-dehydroprogesterone or 17α-acetoxy-6-chloro-2-oxapregna-4,6-diene-3,20-dione, is asyntheticpregnanesteroid and aderivative ofprogesterone and17α-hydroxyprogesterone.[8] It is a derivative of the lesspotentchlormadinone acetate.[5] The medication is the C17αacetateester ofosaterone.[8]
Osaterone acetate was approved for veterinary use in the European Union under the brand name Ypozane in 2007.[1][3][7][8]
Osaterone acetate is thegeneric name of the drug.[1][8] Osaterone is theINNTooltip International Nonproprietary Name of thedeacetylatedparent compound.[8]
Osaterone acetate is marketed under the brand name Ypozane by Virbac throughout the European Union.[1][8]
Osaterone acetate was also investigated in Japan in the treatment ofprostate cancer and BPH in humans but was ultimately never marketed for such purposes.[5][12]
